comisión europeainvestigación ciencias de la vida, genómica y biotecnología aplicadas a la salud...

Comisión Europea Investigación

Ciencias de la Vida, Genómica y Biotecnología aplicadas a la Salud

en el Sexto Programa Marco (2002 - 2006)

Ciencias de la Vida, Genómica y Biotecnología aplicadas a la Salud

en el Sexto Programa Marco (2002 - 2006)


EspacioEuropeo

de Investigación


Una nueva estrategia para la Investigación Europea Una nueva estrategia para la Investigación Europea

Un esfuerzo combinado de la UE y los Estados Miembros para corregir los déficits estructurales de la investigación europea:

Fragmentación y heterogeneidad Falta de recursos Entorno menos favorable para la investigación y la

explotación de resultados

Espacio Europeo de Investigación Espacio Europeo de Investigación (EEI) (EEI) (European Research Area, ERA)(European Research Area, ERA)

Espacio Europeo de Investigación Espacio Europeo de Investigación (EEI) (EEI) (European Research Area, ERA)(European Research Area, ERA)


Política Europea de

Investigación

Política Europea de

Investigación

EEI (ERA)EEI (ERA)

Anteproyecto del futuro de la Investigación en Europa. Gran apoyo al más alto nivel político, científico e industrial. En ejecución.

Programas NacionalesProgramas Nacionales

«Coordinación Abierta»

«Coordinación Abierta»

Programa Marco

Programa Marco

Organizaciones Europeas

Organizaciones Europeas


1.1. Integración de la investigación comunitaria Integración de la investigación comunitaria1.1. Integración de la investigación comunitaria Integración de la investigación comunitaria

1.11.1 Prioridades temáticas Prioridades temáticas1.11.1 Prioridades temáticas Prioridades temáticas 1.21.2 Actividades específicas Actividades específicas1.21.2 Actividades específicas Actividades específicas

2.2. Estructuración del EEI Estructuración del EEI2.2. Estructuración del EEI Estructuración del EEI 3.3. Fortalecimiento de las Fortalecimiento de las bases del EEIbases del EEI

3.3. Fortalecimiento de las Fortalecimiento de las bases del EEIbases del EEI

Sexto Programa Marco (2002-2006)Sexto Programa Marco (2002-2006)


Sexto Programa Marco Euratom excluido (7%)Sexto Programa Marco Euratom excluido (7%)

INTEGRACIÓN DE LA INVESTIGACIÓN EUROPEA (76%)

ÁREAS TEMÁTICAS PRIORIARIAS (64%)

1 2 3 4 5 6 7

PREVISIÓN DE LAS NECESIDADES

CIENTÍFICAS Y TECNOLÓGICAS (12%)

Actividades deapoyo a laspolíticas UE

Nuevas fronteras de lainvestigación,Desarrollos emergentes

Actividades específicas PyMEs

Actividades específicas de CooperaciónInternacional

Cie

nc

ias

de

la

v

ida

, ge

nó

mic

a y

bio

tec

no

log

ía

ap

lic

ad

as

a

la

s

alu

d

Te

cn

olo

gía

s

pa

ra l

a So

cie

da

d d

e l

a

Info

rma

ció

n

Na

no

tec

no

log

ías

, m

at.

In

teli

ge

nte

s,

nu

ev

os

pro

ce

so

s d

e

pro

du

ció

n

Ae

ron

áu

tic

a y

e

sp

ac

io

Se

gu

rid

ad

a

lim

en

tari

a y

ri

es

go

s

pa

ra l

a sa

lud

De

sa

rro

llo

s

os

ten

ible

y

ca

mb

io

glo

ba

l

Ciu

da

da

no

s y

G

ob

ern

an

za

en

la

So

cie

da

d

de

l Co

no

cim

ien

toActividades del Centro Común deInvestigación

ESTRUCTURACIÓN DEL ESPACIO EUROPEO

DE INVESTIGACIÓN (EEI) (15%)FORTALECIMIENTO DE LAS BASES

DEL EEI (2%)

Investig.e Innov.

RecursosHumanosMovilidad

Infraestructurasde Investigación

Ciencia ySociedad

Coordinaciónactividadesinvestigación

Desarrollo de políticasde investigación einnovación

Prioridad 1Prioridad 1::

Ciencias de la vida, genómica y biotecnología Ciencias de la vida, genómica y biotecnología aplicadas a la saludaplicadas a la salud

Prioridad 1Prioridad 1::

Ciencias de la vida, genómica y biotecnología Ciencias de la vida, genómica y biotecnología aplicadas a la saludaplicadas a la salud


1. Ciencias de la vida, genómica y biotecnología aplicadas a la salud

2. Tecnologías para la sociedad de la información (TSI)

3. Nanotecnologías y nanociencias, materiales inteligentes y multifuncionales; nuevos procesos y dispositivos de producción

4. Aeronáutica y espacio

5. Calidad y seguridad de los alimentos

6. Desarrollo sostenible, cambio planetario y ecosistemas

7. Los ciudadanos y la gobernanza en una sociedad basada en el conocimiento

Las 7 prioridades temáticas de investigación** presupuestos pendientes de ratificación

Las 7 prioridades temáticas de investigación** presupuestos pendientes de ratificación

2.255

3.625

1.300

1.075

685

225

2.120

M €


Integración y fortalecimiento del Espacio Europeo de Investigación 2002 - 2006

la integración de la investigación post-genómica en los planteamientos biomédicos y biotecnológicos actuales,

la integración de la investigación multidisciplinaria,

la integración de los centros de investigación para aumentar la coherencia y alcanzar una masa crítica,

…con la participación de los principales estamentos implicados.

Objetivos: mejorar la salud humana y estimular la actividad económica e industrial a través de…

Prioridad 1: Ciencias de la vida, Genómica y Biotecnología aplicadas a la salud



1.1 Advanced genomics and its application for health (€ 1100 M)

1.1.1. Fundamental knowledge and basic tools for functional genomics in all organisms

1.1.2 Applications of knowledge and technologies in the field of genomics and biotechnology for health

1.2.1 Application oriented genomic approaches to medical knowledge and technologies

1.2.2 Combating cancer

1.2.3 Confronting the major communicable diseases linked to poverty

1.2 Combating major diseases (€ 1155 M)




Integration & MultidisciplinarityTechnology <<>> Biology

Integration & MultidisciplinarityTechnology <<>> Biology

Why focus on genomics?Why focus on genomics?

Sequencing of human genome (and other genomes)

Huge opportunities relating to human health

World-class research, vast data >> useful knowledge

Useful knowledge >>understanding disease processes >> applications for health

European competitiveness - integration of public & private research excellence, coherence, critical mass

Stimulate industrial & economic activity EU must avoid becoming a dependent “client”




1.1 Genómica avanzada y sus aplicaciones en la salud

1.1 Genómica avanzada y sus aplicaciones en la salud

Conocimiento fundamental e instrumentos básicos en genómica funcional, en todos los organismos:

Expresión de genes y proteómica, genómica estructural, bioinformática, genética de poblaciones, genómica funcional multidisciplinar, procesos básicos, etc.

Aplicación de los conocimientos y las tecnologías sobre genómica y biotecnología de la salud:

Plataformas tecnológicas, diagnóstico, prevención y terapia, farmacogenómica, células madre, métodos alternativos a la experimentación con animales, etc.




Gene expression and proteomics Developing high throughput tools and approaches for monitoring gene expression and

protein profiles and for determining protein function and protein interactions.

Structural genomics Developing high throughput approaches for determining high-resolution 3-D structures of

macromolecules (>> protein function, drug design)

Comparative genomics and population genetics Developing model organisms and transgenic tools; developing epidemiology tools and

standardised genotyping protocols.

Bioinformatics Developing bioinformatics tools and resources for data storage, mining and processing;

developing computational biology approaches for in silico prediction of gene function and for the simulation of complex regulatory networks.

Multidisciplinary functional genomics approaches to basic biological processes Understanding of the mechanisms underlying fundamental cellular processes, to identify

the genes involved and to decipher their biological functions in living organisms


1.1.2. Applications of knowledge and technologies in genomics and biotechnology for health

1.1.2. Applications of knowledge and technologies in genomics and biotechnology for health

Technological platforms for developments in the field of new diagnostic, prevention and therapeutic tools:

Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches

Development of new diagnostics

Development of new in vitro tests to replace animal testing

Development and testing of new preventive and therapeutic tools (such as somatic gene and stem cell therapies)

Immunotherapies

Innovative research in post-genomics, which has high potential for application

Foster the competitiveness of Europe’s biotechnology industry




1.2 Lucha contra las principales enfermedades

1.2 Lucha contra las principales enfermedades

Aplicación de los conocimientos y las tecnologías de genómica médica, animal y vegetal:

Diabetes, sistema nervioso, enfermedades cardiovasculares, enfermedades raras, resistencia a los antibióticos, cerebro y proceso de envejecimiento, etc.

Cáncer: Estrategias orientadas al paciente, prevención, diagnóstico y tratamiento, redes de coordinación, investigación clínica, etc.

Enfermedades relacionadas con la pobreza: SIDA, malaria y tuberculosis


1.2.1. Application-oriented genomic approaches to medical knowledge and technologies

1.2.1. Application-oriented genomic approaches to medical knowledge and technologies

Combating, diabetes, diseases of the nervous system (Alzheimer’s, Parkinson’s,

CJD, mental illness), cardiovascular diseases and rare diseases Integrating clinical expertise and resources with relevant model systems and advanced

tools in functional genomics to generate breakthroughs in the prevention and management of these diseases

Combating resistance to antibiotics and other drugs: Exploitation of the knowledge of microbial genomes and on host-pathogen interactions

for the development of vaccines and alternative strategies to circumvent the problem of antimicrobial and other drug resistance

Studying human development, the brain and the ageing process Understanding human development from conception to adolescence; exploring the

molecular and cellular determinants of healthy ageing including their interactions with

environmental, behavioural and gender factors

IntegrationGenomic approaches

Disease & health determinants

TranslationBasic knowledge

Clinical applications


1.2.2. Combating cancer1.2.2. Combating cancer

Patient-oriented strategies from prevention to diagnosis and

treatment establishing facilities for the exploitation of research on cancer in

Europe; development of evidence based guidelines for good clinical practice and improved public health strategies

supporting translational research aimed at bringing basic knowledge through to applications in clinical practice and public health

supporting clinical research (clinical trials)

A BROADER APPROACH: The focus not limited to genomics and basic research


1.2.2. Confronting the major communicable diseases linked to poverty

1.2.2. Confronting the major communicable diseases linked to poverty

AIDS, malaria and tuberculosis Developing promising candidate interventions (vaccines, therapies and

HIV microbiocides) - molecular research, pre-clinical testing and proof of principle

Establishing a clinical trial programme in Europe for these diseases to improve coherence and complementarity - special target = interventions for use in developing countries

Establishing an AIDS Therapy Trials Network in Europe.

A BROADER APPROACH: The focus not limited to genomics and basic research

Involvement of patient groups, industry, healthcare providers, physicians, ethicists, regulatory authorities...


Priority 5: Food Quality and SafetyPriority 5: Food Quality and Safety

Safer and environmentally friendly production and processing

Epidemiology of food-related diseases and allergies

Analysis, detection, « traceability » of contaminants and micro-organisms

Organic farming, functional food

Traceability processes along the production chain

Analysis, detection and control of chemical contaminants and micro-organisms

Impact of animal feed

Environmental health risks linked to the food chain


Integración y fortalecimiento del Espacio Europeo de Investigación 2002 - 2006

Proyectos a gran escala:

Proyectos a pequeña escala:

Proyectos Integrados: generación de conocimiento

Redes de Excelencia: interconexión entre expertos

Proyectos específicos de investigación focalizados

Acciones de coordinación Acciones de apoyo específicas

InstrumentosInstrumentos


Objetivos: Aumentar la competitividad y tratar las necesidades sociales más

importantes de la Unión Europea

Proveer resultados aplicables a productos, procesos o servicios

Características: Actividades de investigación complementadas con acciones de

demostración e innovación

Alto nivel de autonomía en la gestión

Ejecutados a través de planes financieros globales

Seleccionados a través de convocatorias / licitaciones

Duración 3-5 años

Proyectos IntegradosProyectos Integrados


Proyectos IntegradosProyectos Integrados

Objetivos científico-

tecnológicos ambiciosos y claramente definidos

Objetivos científico-

tecnológicos ambiciosos y claramente definidos

Fuerte estructura de

gestión

Fuerte estructura de

gestión

Plan de ejecuciónPlan de

ejecución

I+D 4

I+D 1

I+D 2

I+D 3

I+D 5 Demostración

Demostración

FormaciónFormación

Aspectos éticos, diálogo ciencia-sociedadAspectos éticos, diálogo ciencia-sociedad

Transferencia de tecnología, explotación de resultados

Transferencia de tecnología, explotación de resultados

GestiónGestiónGestiónGestión


Diseñadas para fortalecer y extender la excelencia en un tema concreto de investigación

Genuinos “centros de excelencia” virtuales con objetivos a largo plazo y multidisciplinarios

interconectando la masa crítica de recursos y conocimiento necesarios para ser una potencia mundial

en torno a un programa de actividad conjunto con un alto nivel de autonomía de gestión.

Seleccionadas a través de convocatorias abiertas y evaluación por expertos (peer review)

Financiadas hasta varios millones de € anuales duración de 5 años o incluso más, si es necesario, para crear una

integración duradera

Redes de ExcelenciaRedes de Excelencia


Redes de ExcelenciaRedes de ExcelenciaConsejo de Administración

To structure the EU research potential

by integrating research capacities

• Joint research activities• Integrating activities• Spreading of excellence• Common management

Representantes de los Organismos

Financiadores

Management Group

Com

isió

n E

uro

pea

Representante de Organización Asociada

Jefe del Grupo de Investigación

Consejo Directivo

• Actividades de Investigación conjuntas• Actividades de integración• Diseminación de la Excelencia (Formación)• Gestión común

Estructurar el potencial investigador de la UE mediante la integración de las capacidades de investigación existentes


Specific targeted research projects

(evolved form of R&D shared-cost projects FP5) max 50%

Funds research activities of a more limited scope

In particular, modest participants, including SMEs and candidate countries

Specific Support Actions For example:

Conferences, seminars, studies & analysis, experts

groups, operative support and dissemination,

information and communication activities.

Other Instruments Other Instruments

Up to 100% of the budget

Up to 100% of the budget


Derechos de Propiedad IntelectualDerechos de Propiedad Intelectual

Experiencia del 5° PM + consultas con sectores industriales y académicos: Los Derechos de Propiedad Intelectual (IPR) se simplificarán. Los miembros del consorcio establecerán los acuerdos que procedan.

Los participantes son los propietarios de los resultados que hayan generado

Énfasis en el uso de los resultados y en su diseminación si es apropiado o si los resultados no se usan

Las PyMEs son las propietarias de los resultados generados en las actividades de I+D PyMEs

Completo y clarificado en un solo documentoCompleto y clarificado en un solo documento


Evaluation processEvaluation process

Calls for proposals

normally preceded by expressions of interest

Simplified proposal-making

reflecting evolutionary nature of the network

Evaluation by a strengthened peer-review system

in stages, possibly involving individual reviews, panel sessions, hearings of applicants…

Specific criteria include potential impact on strengthening Europe’s excellence excellence of the network members extent, depth and lasting nature of the integration contribution to spreading excellence management and governance of the network


Integ

ran

do

la in

ves

tigac

ión

Integ

ran

do

la in

ves

tigac

ión

Lucha contra las resistencias a los antimicrobianos y otros fármacos

Explotación del conocimiento de los genomas microbianos y de las interacciones patógeno-hospedador ------> vacunas, estrategias alternativas

Estrategias para el uso óptimo de fármacos antimicrobianos

Red europea de vigilancia epidemiológica y control de enfermedades transmisibles.

Aplicación de instrumentos a las prioridades temáticas de investigación del 6º PM

Aplicación de instrumentos a las prioridades temáticas de investigación del 6º PM

Ejemplo. Prioridad 1.2: Lucha contra las principales enfermedadesEjemplo. Prioridad 1.2: Lucha contra las principales enfermedades

Aplicación de los conocimientos y las tecnologías de la genómica

Enfermedades relacionadas con la pobreza: tuberculosis, malaria y SIDA


P R O Y E C T O S I N T E G R A D O SP R O Y E C T O S I N T E G R A D O SP R O Y E C T O S I N T E G R A D O SP R O Y E C T O S I N T E G R A D O S

FármacosFármacos VacunasVacunas MicrobicidasMicrobicidas

PLATAFORMA EUROPEA DE ENSAYOS CLÍNICOS PARA PAÍSES EN VÍAS DE

DESARROLLO (Artículo 169)

RED EUROPEA DE ENSAYOS

CLÍNICOS:TERAPIAS CONTRA EL SIDA

(Red de Excelencia)

RED EUROPEA DE ENSAYOS

CLÍNICOS:TERAPIAS CONTRA EL SIDA

(Red de Excelencia)

PreclínicaPreclínica

Descubr. MoléculaDescubr. Molécula

GenómicaGenómica

ClínicaClínica

VIH/SIDAVIH/SIDAVIH/SIDAVIH/SIDA

FármacosFármacos VacunasVacunas VacunasVacunas FármacosFármacos

MalariaMalariaMalariaMalaria

TBTBTBTB

Investigación

Aplicación de instrumentos y prioridades temáticas de investigación del 6º PM

Aplicación de instrumentos y prioridades temáticas de investigación del 6º PM


An Example of Integrated Project: SPINEAn Example of Integrated Project: SPINE

Structural Proteomics in Europe

First pilot experience of an IP, already from FP5

Objective: to develop high throughput technologies to solve 300-500 protein structures relevant to human health

From production to structure analysis 3-year programme 17 partners from 7 countries 13,7 M €


Modalidades de participaciónModalidades de participación

¿ Quién puede participar ?

Toda entidad legal

Países candidatos y asociados al PM gozarán de las mismas condiciones que los Estados Miembros de la UE

Las Organizaciones Europeas de Investigación (CERN, ESA, EMBO, etc. ) tendrán el mismo estatus que cualquier entidad de los Estados Miembros

Proyectos Integrados y Redes de Excelencia: mínimo 3 participantes (de al menos 3 estados miembros o asociados)

Participación individual posible en becas y acciones de apoyo


La información sobre los proyectos financiados por la UE (5º Programa Marco), incluyendo los datos de los participantes, puede consultarse en:

En el sitio web de Cordis se publican las manifestaciones de Interés recibidas (6º Programa Marco) y una base de datos de partners:

¿Cómo encontrar socios europeos?¿Cómo encontrar socios europeos?

http://www.cordis.lu/life/src/projects.htm

http://www.cordis.lu/fp6/


Convocatoria de Expresiones de InterésConvocatoria de Expresiones de Interés

Una oportunidad para la comunidad investigadora europea de intervenir en la preparación de las primeras convocatorias del

6º Programa Marco

Consulta a la comunidad científica sobre su disposición a llevar a cabo Proyectos Integrados o Redes de Excelencia bajo las 7 prioridades temáticas del 6º Programa Marco.

Los resultados se usarán para definir los Programas de Trabajo y para preparar las Convocatorias del 6º PM

La participación facilitará la comprensión del potencial de los nuevos instrumentos por parte de la comunidad investigadora.

Consulta a la comunidad científica sobre su disposición a llevar a cabo Proyectos Integrados o Redes de Excelencia bajo las 7 prioridades temáticas del 6º Programa Marco.

Los resultados se usarán para definir los Programas de Trabajo y para preparar las Convocatorias del 6º PM

La participación facilitará la comprensión del potencial de los nuevos instrumentos por parte de la comunidad investigadora.


Expressions of Interest -ResultsExpressions of Interest -Results

FP6: Close to 12.000 EoIs received and evaluated

Priority one: Close to 2.000 EoIs received Evaluated with the help of over 200 external experts Proposals address 2/3 integrated projects and 1/3 networks

Priority one IP NoE Notspecified

Total

Fundamental genomics 288 190 45 523Genomics and applied biotechnology 240 125 36 401Medical genomics 459 219 24 702Cancer 196 102 4 302Poverty related diseases 41 28 69Total 1224 664 109 1997


65%

25%

4%6%

HigherEducation

ResearchInstitute

Industry

Other

65%

25%

4%6%

HigherEducation

ResearchInstitute

Industry

Other

Enormous response for the first priority (life sciences, genomics & biotechnology for health

Only 4% of EoIs from industry (including SMEs)

Good response from the candidate countries (10% of EoIs)

All EoIs and an overall report are published on www.cordis.lu

Distribution of EOIs by type of submitting institution

Distribution of EOIs by type of submitting institution


From 12000 EoI to a workprogramme for... Structural Genomics

From 12000 EoI to a workprogramme for... Structural Genomics

Structural genomics: 32 EoI Research topics of strategic importance for Europe considered ready for

possible implementation:

IP:

Structure determination of large protein complexes.

Development of new hardware and software for the implementation of innovative automated technologies at synchrotron sites for high throughput structural genomics.

High throughput 3D-structure determination of membrane proteins and membrane protein complexes.

Comparative structural biology of viral replication

NoE: Supramolecular analysis of large protein complexes by 3D electron microscopy in situ.


Plus...Plus...

STREP (methods for the production of crystals)

Specific Support Actions (meetings with third countries, workshops, etc)

Support for Research Infrastructures

Mobility

EUROPEAN FORUM ON GENOME RESEARCHNational & Supranational Policy-makers + Scientists

Possibility of forming a steering group on Structural Genomics

Workshop under the umbrella of the Forum--> could be funded by FP6


Más InformaciónMás Información

General information: http://europa.eu.int

General information on research: http://europa.eu.int/comm/research

Information on research programmes: http://www.cordis.lu

6th Framework Programme:http://europa.eu.int/comm/research/nfp.html

Expressions of Interests: http://www.cordis.lu/fp6/eoi-instruments

Information requests:[email protected]

Help-Desk on Expressions of Interests (priority 1): [email protected] / [email protected]

Structural Genomics: [email protected]


Gene expression and proteomics:- IP: Global in situ gene expression analysis in mouse models and human tissues.- IP: Development and application of high throughput proteomics technologies for thegeneration of a large data set of protein-protein interactions.- IP: Development of advanced array technologies for analysis with high precision andsensitivity of large sets of proteins, DNA and RNA.

Comparative genomics and population genetics:- IP: Integrated tools for functional genomics of Zebrafish as a model for human

development and disease mechanisms.- IP: Development of in-vivo imaging technologies for phenotyping and functional analysis

in cells and animal models.- IP: Large scale RNA interference screening in Arabidopsis for the identification of

important gene functions underlying biological processes relevant to health.- IP: Developing new molecular tools and approaches for phenotyping human populations.- NoE: Standardisation and integration of genomic and phenotypic information to

characterise bacterial diversity with relevance to human health.- NoE: Co-ordinating population sample collections in Europe, standardising genotypingmethods for identifying and interpreting sequence variations, linkage disequilibrium andhaplotype patterns.

From 12000 EoI to a workprogramme for... Fundamental Genomics



Multidisciplinary functional genomics approaches to basic biological processes:

- IP: Integrated comparative and functional genomics approaches for studying cell cycle.- IP: Functional genomics of non-human embryonic stem cell differentiation.- IP: Functional genomics of erythroid development and disorders.- IP: Multidisciplinary approaches of functional genomics to study lymphangiogenesis.- IP: Integration of different expertise, animal models and functional genomics platforms to

study the kidney in health and disease.- IP: Functional genomics approaches to the study of peroxisomes in health and disease.- IP: Functional genomics of inner ear or retina development and disorders.- IP: Functional genomics approaches to study DNA damage and repair mechanisms in

health and disease.- NoE: Animal models and functional genomics approaches to study the immune system ormuscles in health and disease.- NoE: Large epidemiological studies of X-linked syndromes.- NoE: Epigenetics: chromatin dynamics, non-coding RNA, imprinting and silencing.- NoE: Multidisciplinary approaches of functional genomics understand the basic molecularmechanisms of inflammation and their links to inflammatory disorders.- NoE: Functional genomics approaches to decipher ubiquitin-proteasome and/or relatedpathways.




Bioinformatics:

- IP: Development of an integrated software platform to tackle genomic sequence-structure-function relationships.

- NoE: Bioinformatics and genomics grid for European research.- NoE: Developing methods and resources in bioinformatics to focus on human

genome annotation.




Rational and accelerated development of new, safer and more effective drugs including pharmacogenomics approaches:

IP: Blood substitutes. IP: Antiviral therapeutics. IP: New drugs from novel sources. Genome based individualised medicines (NoE and/or IP). Novel therapies for neurodegenerative disorders in CNS and PNS (NoE and/or IP). Genome-based anti-psychotic therapies (NoE and/or IP). Signal transduction pathways as targets for disease detection and treatment (NoE or IP). NoE: Development of medicines in pediatrics. NoE: Computer assisted modelling for drug discovery and clinical trials.

Development of new diagnostics : NoE: In vivo molecular imaging. NoE: Reference systems for genetic testing. Non-invasive (including prenatal) diagnostics; development of markers for ante- and

neonatal screening (NoE and/or IP).

From 12000 EoI to a workprogramme for... Applied Genomics



Development of new in vitro tests to replace animal experimentation :In vitro alternatives to animal and human toxicology testing : IP: development of innovative methods, technology, strategies. NoE: application of in vitro methods.

Development and testing of new preventive and therapeutic tools such as somatic, gene and cell therapies (in particular stem cell therapies) and immunotherapies :

Tissue engineering and regeneration therapies : IP: connective tissue disorders : bone diseases, osteoarthritis. IP: organ repair : hepatic, hemopoietic, neural tissue. NoE: biobanks. Stem cells: IP: Translation of stem cell biology into new cell-based therapies and novel targets for drugdevelopment and other therapeutic products. IP: Stem cell development for the regeneration of hemopoietic, hepatic, cardiac, neural,mesenchymal and connective tissues. IP: Stem cell development, technical standardisation, benchmarking, development of

reference materials.




Development and testing of new preventive and therapeutic tools such as somatic, gene and cell therapies (in particular stem cell therapies) and immunotherapies :

(cont.) NoE: Stem cells therapies : standardisation, characterisation and protocol validation. Immunotherapy : development, testing and response monitoring of immune system-basedtechnologies for application against a wide range of diseases: IP: new improved vaccine technologies. IP: immunotherapy for auto-immune diseases. IP: plant based vaccines– plant biotechnology for global health. Gene and cell therapies: IP: viral and non-viral delivery systems. NoE: cell targeting. NoE: standardisation and characterisation in gene therapy. gene therapy for genetic diseases (NoE and/or IP). Inflammation and immunoregulation : IP: dendritic cells, chemokines, cytokines. allergy, autoimmunity, inflammatory disease (NoE and/or IP). prevention and treatment of disease through modulation of the immune system (NoE

and/or IP).




Innovative research in post-genomics, with high potential for application : Clinical applications of post-genomic information: IP: functional analysis of human genome and its application to diagnosis and therapy ofdiseases, including mitochondrial disorders. IP: adverse reactions to drugs, in particular those of immunological origin. IP: quality and safety control of new tools (gene vectors, stem cells) for clinical use. NoE: Optimisation, standardisation and quality assessment and assurance of post-

genomic technology.

Post-genomic approaches : IP: for allergy and autoimmune diseases. IP: for complex multifactorial diseases. for the development of new tools for the rapid diagnosis of pathogenic infection and new

targets for anti-microbial agents (NoE and/or IP). IP: New strategies for large scale analysis and high throughput screening in the

postgenomic. NoE: RNA tools for gene function analysis.




Epidemiology of food-related diseases and allergies.Validated food information database for Europe (NOE)Gene-nutrient interaction (IP)Epidemiology of food allergy (IP)Lipid metabolism and chronic diseases (IP)Influence of nutrition and lifestyle on healthy ageing (IP)

Impact of food on health.Functional genomics in relation to food, nutrition and health (NE)Microbes and gut health (IP)Programming effects of early nutrition on long-term health (IP)Determinants of food choice(NOE)Healthy ageing through diet. (NOE)Enhancing health benefits of cereals in the diet (IP)Risk-benefit analysis of phyto-estrogens, as an important class of bio-active compounds, on human health. (IP)Integrated strategies to prevent obesity and associated diseases (IP)Dietary fatty acids: optimised supply and response (NOE)Food safety and communication (NOE)

From 12000 EoI to a workprogramme for... Food Quality and Safety



"Traceability" processes all along the production chain.Authenticity of declared origins (IP)Critical Control Points in safe primary production and environmental protection management (NOE)

Methods of analysis, detection and control.Prevention, control and treatment of prion diseases (NOE)Control strategies for newly and future emerging foodborne pathogenic microorganisms. (IP)New perspectives on health risks from cooked foods and food products (IP)Prevention and control of zoonosis diseases (NOE)Microbial food safety, consumer risk perception and alternative food production. (IP)New biotechnologies for monitoring chemical contaminants in food products (IP)




Safer and environmentally friendly production methods and healthier foodstuffs.

Plant systemsDevelopment, monitoring and assessment of safe biocontrol agents. (NE)Biological Engineering of Soil- Roots Interactions (IP)Information Technology and other new technologies for low input multifunctional agriculture and protected cultivation (NOE)Safe use of organic wastes in agricultural production systems (NOE)Safe production under biotic and environmental stress conditions (IP)Exploitation of plant biodiversity to reduce pesticide application for disease control (IP)High throughput phenotyping and metabolic analysis for optimising end product quality in food crops (IP)“Tilling” as a reverse-genetics approach to improve food crops (IP)Improving nutritional value and sustainability in cereals (IP)




Safer and environmentally friendly production methods and healthier foodstuffs.

Animal SystemsEpizootic disease diagnosis and control (NOE)Sustainability of resources in aquaculture (finfish and shellfish) (NOE)Animal Welfare (IP)Fundamental animal genomics (NOE)Genomics of host-pathogen interactions in livestock disease including zoonotic diseases. (NOE)Generic platform to improve the immunological basis for protection against disease (includingaquaculture) (IP)European apiculture research co-ordination. (NOE)Biodiversity in livestock (including aquaculture) (NOE)




Impact of animal feed, on human healthSafe use of organic wastes in agricultural production systems (IP)New strategies to improve grain legumes for food and feed (IP)

Environmental health risks.Environmental causes and mechanisms responsible for the increase in allergies (IP)Exposure to environmental chemical residues (NOE)Endocrine disrupters (NOE)Environmental cancer risk (IP)Pathogens and toxins in food and water (IP)

Food Chain (EOI which cross all or several of the research tasks)Food Quality and Safety in the European Organic Supply Chain (NOE)Seafood for Consumer Health and Well-being (IP)Aquaculture for a High Quality and Safe Product (NOE)Development of an Advanced OSGi-based Technology for Continuous Remote Quality Managementduring Refrigerated Transport of Chilled and Frozen Foods (IP)Improving human health by optimising plant food chain and plant biodiversity (IP)Improving the eating quality and safety of beef for the European consumer (IP)



comisión europeainvestigación ciencias de la vida, genómica y biotecnología aplicadas a la salud...

Documents